B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144

Benzinga · 1d ago
B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $123 to $144.